New drug combo aims to stall advanced breast cancer
NCT ID NCT07037199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new treatment plan for people with a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low). Participants first receive trastuzumab rezetecan alone for several months, then switch to a combination of CDK4/6 inhibitors and hormone therapy. The goal is to see if this sequence can delay cancer growth. The study will enroll 45 patients and track how long they live without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab rezetecan, CDK4/6 inhibitors (dalpiciclib, abemaciclib, ribociclib, palbociclib), and endocrine therapy (fulvestrant or aromatase inhibitors)
- What this could lead to
- If successful, this sequential treatment approach could provide a new option to control advanced breast cancer for longer before the disease worsens.
- What could go wrong
- This is a small, early-phase trial with only 45 participants, so results may not apply to all patients. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer
- Could a pill replace an IV for advanced breast cancer treatment?